PMID: 11032464Oct 14, 2000Paper

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group)

European Psychiatry : the Journal of the Association of European Psychiatrists
P CarrièreT Lempérière

Abstract

In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months. More patients in the haloperidol group withdrew prematurely (44% vs 26%; P = 0.0077) due to a higher incidence of adverse events. Amisulpride was at least as effective as haloperidol in reducing the Brief Psychiatric Rating Scale (BPRS) total score (-27.3 vs -21.9) (non-inferiority test; P < 0.001). The PANSS positive score improved to a similar extent in both groups whilst improvement in the PANSS negative score was significantly greater with amisulpride (-10.5 vs -7.2; P = 0.01). The percentage of responders on the Clinical Global Impression scale was also significantly greater with amisulpride (71% vs 47%; P < 0.001). Both the Quality of Life Scale (QLS) and the Functional Status Questionnaire (FSQ) improved to a significantly greater extent under amisulpride. Haloperidol was associated with a greater incidence in extrapyramidal symptoms and with a greater increase in the Simpson-Angus score than was seen with amisulpride (0.32 vs 0.02; P < 0.001). In conclusion, amisulpride is globally superior to haloperidol in the treat...Continue Reading

References

Feb 1, 1991·Archives of General Psychiatry·A RifkinM Wachspress
Aug 1, 1990·Archives of General Psychiatry·T Van PuttenJ Mintz
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
May 1, 1986·Journal of General Internal Medicine·A M JetteT L Delbanco
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Jun 1, 1994·The American Journal of Psychiatry·S R Marder, R C Meibach
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Sep 1, 1995·International Clinical Psychopharmacology·D E Casey
Mar 1, 1996·Psychopharmacology·C M BeasleyS Hamilton
May 1, 1997·International Clinical Psychopharmacology·B ScattonH Schoemaker
Aug 1, 1997·Journal of Clinical Psychopharmacology·G Chouinard, P S Albright
Jul 31, 1998·Journal of Urban Health : Bulletin of the New York Academy of Medicine·K Davis, D Sandman
Nov 5, 1999·The Journal of Clinical Psychiatry·B C HoN C Andreasen

❮ Previous
Next ❯

Citations

Jul 10, 2007·Psychopharmacology·Stefan LeuchtWerner Kissling
Jul 20, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J PeuskensA Puech
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan Leucht, Rolf R Engel
Feb 9, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtStefan Wagenpfeil
Aug 15, 2006·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Jan 25, 2002·International Clinical Psychopharmacology·P SaleemH Loo
Mar 11, 2006·International Clinical Psychopharmacology·George N PapadimitriouConstantin R Soldatos
Mar 11, 2006·International Clinical Psychopharmacology·Jean-Pierre OliéRuoyong Yang
May 11, 2011·PloS One·Toshi A Furukawa, Stefan Leucht
Jan 1, 2010·Drug, Healthcare and Patient Safety·Mario F JuruenaIrismar Reis de Oliveira
Jun 27, 2009·Neuropsychiatric Disease and Treatment·Ann M Mortimer
Mar 25, 2008·Therapeutics and Clinical Risk Management·Philippe NussCédric Tessier
Jul 5, 2008·Clinical Drug Investigation·Luca PaniKöksal Alptekin
Nov 23, 2013·Schizophrenia Research·Myrto T SamaraStefan Leucht
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Stefan LeuchtRolf Engel
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Mar 30, 2016·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Ying LiangXin Yu
Feb 10, 2006·Neuroscience and Biobehavioral Reviews·Pamela J Marsh, Leanne M Williams
Aug 31, 2002·Current Medical Research and Opinion·T BurnsK Demyttenaere
Apr 10, 2003·The Psychiatric Clinics of North America·Robin Emsley, Piet Oosthuizen
Dec 11, 2014·Statistics in Medicine·Vasiliki DimitrakopoulouGeorgia Salanti
Feb 4, 2010·Current Medical Research and Opinion·Philippe Nuss, Cedric Tessier
Nov 7, 2002·Current Medical Research and Opinion·Y Lecrubier
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Jul 11, 2014·Evidence-based Mental Health·Dimitris MavridisGeorgia Salanti
Oct 25, 2016·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yongmin KimWon-Myong Bahk
Mar 3, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Jul 2, 2004·Therapeutic Drug Monitoring·Christoph HiemkeMatthias J Müller
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Jun 22, 2002·The Cochrane Database of Systematic Reviews·N E MotaB G Soares
Dec 1, 2011·Therapeutic Advances in Psychopharmacology·Zeynep KotanSelçuk Kirli
Oct 19, 2006·Journal of Psychopharmacology·Simon Burton
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Maren CarbonChristoph U Correll
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
May 7, 2005·Journal of Clinical Psychopharmacology·Marius K NickelThomas H Loew
Jul 4, 2002·Current Medical Research and Opinion·Ben Green
Jan 7, 2006·Biometrical Journal. Biometrische Zeitschrift·S Lange, G Freitag
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here